Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors

Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing. The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.

Proceeds will support ongoing mid- to late-stage clinical development programs for the Company’s lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit the activity of B cells, plasmablasts, and CD19-expressing plasma cells.

The obexelimab clinical programs include an ongoing Phase 3 registration-directed trial in IgG4-Related Disease, two planned Phase 2 randomized controlled trials in Multiple Sclerosis and Systemic Lupus Erythematosus, and an ongoing open label Phase 2 trial in Warm Autoimmune Hemolytic Anemia.

“We are pleased and appreciative of the support we have received from this group of tremendous life sciences investors as we advance the ongoing obexelimab development program across multiple auto-immune diseases,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world. This financing enables us to complete multiple potentially value driving clinical programs.”

“We are excited to support Zenas’ continued progress toward its goal of becoming a global leader in innovative immunology-based therapies, and we are confident in the capabilities of this exceptional team to advance the comprehensive development program for obexelimab across multiple potential indications,” said Jake Nunn, venture partner at SR One. “At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care. We are proud to serve as lead investor alongside an exceptional syndicate and look forward to supporting Zenas in advancing a pipeline of innovative new therapeutic approaches for patients living with inflammatory and immune-mediated diseases.”

About Obexelimab

Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit B-lineage cell activity.  Obexelimab has demonstrated clinical activity and was well-tolerated in five clinical trials, including in several autoimmune diseases, in which 198 subjects were dosed. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4-Related Disease and a global Phase 2/3 study in patients with Warm Autoimmune Hemolytic Anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under way. 

More information on the Phase 3 (INDIGO) study for the treatment of IgG4-Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 2/3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573. 

About Zenas BioPharma

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Zenas’ experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

About SR One

SR One is a transatlantic biotechnology venture capital firm that collaborates with entrepreneurs and investment partners in an effort to build elite biotechnology companies. The Company’s mission is to translate innovative technologies and scientific discoveries into next-generation medicines with the potential to benefit patients with significant unmet medical needs. SR One leadership has worked together to build and invest in biotechnology companies for more than a decade. Working alongside the investment team, SR One’s venture partners bring deep operational experience to help company creation initiatives and support portfolio companies with financing and corporate strategies. SR One has offices in Redwood City, CA, and Philadelphia, PA, in the US and London in the UK. For more information, please visit www.srone.com.

About NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of December 31, 2023, and invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions. For more information, please visit www.nea.com.

About Norwest Venture Partners

Norwest Venture Partners is a global venture and growth equity investment firm managing more than $15.5 billion in capital. Since its inception, Norwest has invested in more than 700 companies and currently partners with more than 230 companies in its venture and growth equity portfolio. The firm invests in early- to late-stage businesses across key sectors with a focus on enterprise, consumer and healthcare. The Norwest team offers a deep network of connections, extensive operating experience, and a wide range of impactful services to help CEOs and founders scale their businesses. Norwest has offices in Menlo Park and San Francisco, Calif.; Mumbai, India; and Tel Aviv, Israel. For more information, please visit www.nvp.com.

About Delos Capital

Delos Capital is a life sciences investment firm that partners with extraordinary teams pursuing breakthrough medicines that meaningfully improve the lives of patients. We are a collaborative, global team of seasoned biotech investors, company-builders, operators, and industry analysts, and we aim to serve the companies into which we invest by bringing both capital and substantive biotech expertise. We have designed, built, financed, and supported both novel platforms and approved medicines that strengthen hundreds of millions of lives across the world. Our global team is spread across offices in Cambridge, MA and in East Asia, allowing us to blend deep experiences operating at the epicenter of global biotech venture with proprietary insights into innovations from emerging biotech clusters. Delos Capital currently manages three funds, with ~US$600 million in total capital under management. For more information, please visit www.deloscapital.com.

Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com

 


Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

THỦ THUẬT HAY

Cách tắt thông báo Windows Defender Summary trên Windows 10

Windows Defender là trình bảo mật máy tính, phát hiện virus có sẵn trên máy tính Windows 10. Và người dùng sẽ nhận được chi tiết hoạt động của công cụ thông qua thông báo Windows Defender Summary.

3 cách tra điểm thi vào lớp 10 tại Hà Nội qua điện thoại chính xác nhất

Ngày 7/6 vừa qua, Sở GD&ĐT Hà Nội đã tổ chức kỳ thi tuyển sinh vào lớp 10 năm học 2018 - 2019. Để giúp thí sinh cũng như các bậc phụ huynh nhanh chóng cập nhật kết quả thi cho con em mình, VNPT Vinaphone đã cung

Hướng dẫn tạo tài khoản Viettel Post trên điện thoại Android và iOS mới nhất

ViettelPost có hệ thống bưu cục phân bố đồng đều rộng khắp cả nước, cho nên mọi giao - nhận và chuyển phát hàng hóa diễn ra rất nhanh chóng, thuận tiện và dễ dàng. Và nhờ có hạ tầng hiện đại, ViettelPost luôn đảm bảo

Hưỡng dẫn thiết lập phần mềm, tự động chạy khi khởi động trên OS X

Đôi khi bạn muốn thiết lập để một số ứng dụng tự động chạy mỗi khi khởi động máy Mac. Thủ thuật nhỏ dưới đây sẽ hưỡng dẫn bạn cách để điều hướng một trương trình nào đó chạy ngay sau khi khởi động.

Hướng dẫn tải file ISO của Windows 10 về máy tính

Dưới đây là các bước hướng dẫn để tải file ISO Windows 10 chính thức từ Microsoft về máy tính.

ĐÁNH GIÁ NHANH

“Mổ xẻ” Dell XPS 17 9700: có gì mà giá tới tận trên 50 triệu đồng?

Dell XPS 17 9700 là một chiếc Ultrabook khổng lồ cả về kích thước lẫn hiệu năng. Những tin đồn về Dell XPS 17 9700 từ đầu năm nay phần lớn đều đã thành hiện thực. Ở Việt Nam, chiếc máy này đang được bán với giá tham

Đánh giá mainboard MSI Z370 Gaming Pro Carbon AC – Nền tảng mạnh, ép xung linh hoạt

Z370 Gaming Pro Carbon AC được xem là đại diện tiêu biểu cho dòng bo mạch Performance Gaming hướng đến game thủ và người dùng đam mê máy tính. Chính vì vậy mà sản phẩm được MSI ưu ái trang bị đầy đủ tính năng tiên

Đánh giá Mitsubishi Outlander: crossover đẹp và chất, đẳng cấp Nhật Bản

Sau hành trình dài trải nghiệm khám phá, chúng tôi mới hiểu vì sao Mitsubishi Motors Việt Nam lại tự tin vào quyết tâm giành chiến thắng khi tung Outlander mới vào thị trường cạnh tranh đầy khốc liệt.